Julio Rosenstock 1, Harpreet S Bajaj 1, Andrej Janež 1, Robert Silver 1, Kamilla Begtrup 1, Melissa V Hansen 1, Ting Jia 1, Ronald Goldenberg 1, NN1436-4383 Investigators
Main idea: Once-weekly treatment with insulin icodec had glucose-lowering efficacy and a safety profile similar to those of once-daily insulin glargine U100 in patients with type 2 diabetes.
It is thought that a reduction in the frequency of basal insulin injections might facilitate treatment acceptance and adherence among patients with type 2 diabetes. Insulin icodec is a basal insulin analogue designed for once-weekly administration that is in development for the treatment of diabetes. A 26-week, randomized, double-blind,double-dummy, phase 2 trial was conducted to investigate the efficacy and safety of once-weekly insulin icodec. The primary endpoint was the change in glycated hemoglobin level from baseline to week 26. A total of 247 participants were randomly assigned (1:1) to receive icodec or glargine. Baseline characteristics were similar in the two groups. There was no between-group difference in insulin-related key adverse events. Most adverse events were mild, and no serious events were deemed to be related to the trial medications.